ICER Colloquium Series, Pricing in a Pandemic | Session Two: Cost-Effectiveness and Value-Based Pricing

YOU ARE INVITED

ICER Colloquium Series, Pricing in a Pandemic: Options, Debate, a Path Forward

Session Two: Cost-Effectiveness and Value-Based Pricing

  • Webinar Date: July 31, 2020, from 12-1:30 pm ET
  • Speakers:
    • Jon Campbell, PhD, Associate Professor, Pharmaceutical Outcomes Research, University of Colorado
    • Bobby Dubois, MD, PhD, Chief Science Officer and Executive Vice President, National Pharmaceutical Council
    • Craig Garthwaite, PhD, Associate Professor of Strategy, Kellogg School of Management, Northwestern University
    • Steve Miller, MD, Chief Clinical Officer, Cigna
    • Eleanor Perfetto, PhD, Executive Vice President of Strategic Initiatives, National Health Council
  • Audience: Free and open to the public

Before the talk, take a look at our white paper on “Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19.”

WATCH WEBINAR RECORDING

 
 
The Institute for Clinical and Economic Review invites all patient organizations and the general public to attend a webinar to learn more about ICER’s mission, patient engagement, and proposed enhancements for evaluating medicines and other health care interventions. Leaders in government, business, and society all seek to adopt policies that will spur the development of treatments and preventive therapies for COVID-19 that can be delivered as rapidly as possible in an affordable and equitable manner. One critical issue will be how new treatments will be priced to ensure that this goal can be met. In the exceptional circumstances of the coronavirus pandemic the early decisions made regarding pricing policy will guide further decisions in the coming months that will have enormous consequences for the United States and the rest of the world.

ICER published a white paper to inform public and policy maker discussion of “Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19.”  To complement the white paper, ICER will host a three-part online colloquium series of 90-minute webinars featuring leading health policy and industry experts from around the country who will debate the advantages and disadvantages of many different potential approaches to developing and pricing medicines during a pandemic.

The second colloquium will cover value-based pricing through which cost-effectiveness analysis is used set a ceiling price based on the degree of added benefit for patients and society.

REGISTER FOR WEBINAR